Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

The drug is already approved in the EU to treat certain cases of non-small lung cancer, as well as oesophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma. Mark ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Key exclusion criteria included a history of severe immune-related adverse events from prior immune checkpoint inhibitor use, untreated or symptomatic central nervous system metastases, and a history ...

Researchers have shown that activation of the protein YAP, which helps tumours grow, differs between two- and three-dimensional culture models, pointing to more predictive systems for testing cancer ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...